EDITORIAL: How to market a controversial pill
The FDA's recent approval of the abortion pill mifepristone, more commonly known as RU-486, brings with it several important communications issues, the least of which is the never-ending debate over abortion itself.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>